A common rejection module (CRM) for acute rejection across multiple organs identifies novel therapeutics for organ transplantation

Journal of Experimental Medicine

Volumn 210, Issue 11, 2013, Pages 2205-2221

  Khatri, Purvesh ^a,b   Roedder, Silke ^a,c   Kimura, Naoyuki ^a   De Vusser, Katrien ^d   Morgan, Alexander A ^a   Gong, Yongquan ^a   Fischbein, Michael P ^a   Robbins, Robert C ^a   Naesens, Maarten ^c,d   Butte, Atul J ^a   Sarwal, Minnie M ^a,c  

^a STANFORD UNIVERSITY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BORTEZOMIB; CYCLOSPORIN; DASATINIB; DOXYCYCLINE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PRAVASTATIN; PZ 0001; S 1021; SIMVASTATIN; SULINDAC; TACROLIMUS; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CHRONIC MYELOID LEUKEMIA; COHORT ANALYSIS; COMMON REJECTION MODULE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; GENE CONTROL; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENETIC DATABASE; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMAN; HUMAN TISSUE; HYPERLIPIDEMIA; IMMUNOREGULATION; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

ALLOGRAFTS; ANIMALS; BIOPSY; COHORT STUDIES; DATABASES AS TOPIC; DISEASE MODELS, ANIMAL; DRUG APPROVAL; ELECTRONIC HEALTH RECORDS; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORKS; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HEPTANOIC ACIDS; HUMANS; KIDNEY; KIDNEY TRANSPLANTATION; META-ANALYSIS AS TOPIC; MICE; MICE, INBRED C57BL; MOLECULAR TARGETED THERAPY; ORGAN SPECIFICITY; PYRIMIDINES; PYRROLES; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; THIAZOLES; TRANSPLANTATION; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84886849594     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20122709     Document Type: Article

References (77)

1. Arnadottir, M., L.O. Eriksson, H. Thysell, and J.D. Karkas. 1993. Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutarylcoenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin. Nephron. 65:410-413. http://dx.doi.org/10.1159/000187521
2. Asberg, A., A. Hartmann, E. Fjeldså, S. Bergan, and H. Holdaas. 2001. Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients. Am. J. Transplant. 1:382-386. http://dx.doi.org/10.1034/j.1600-6143.2001.10415.x
3. Baron, U., S. Floess, G. Wieczorek, K. Baumann, A. Grützkau, J. Dong, A. Thiel, T.J. Boeld, P. Hoffmann, M. Edinger, et al. 2007. DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3(+) conventional T cells. Eur. J. Immunol. 37:2378-2389. http://dx.doi.org/10.1002/eji.200737594
4. Blake, S.J., A. Bruce Lyons, C.K. Fraser, J.D. Hayball, and T.P. Hughes. 2008. Dasatinib suppresses in vitro natural killer cell cytotoxicity. Blood. 111:4415-4416. http://dx.doi.org/10.1182/blood-2008-02-138701
5. Butte, A.J. 2008. Translational bioinformatics: coming of age. J. Am. Med. Inform. Assoc. 15:709-714. http://dx.doi.org/10.1197/jamia. M2824
6. Campana, C., I. Iacona, M.B. Regazzi, A. Gavazzi, G. Perani, V. Raddato, C. Montemartini, and M. Viganò. 1995. Efficacy and pharmacokinetics of simvastatin in heart transplant recipients. Ann. Pharmacother. 29:235-239.
7. Chatterjee-Kishore, M., R. Kishore, D.J. Hicklin, F.M. Marincola, and S. Ferrone. 1998. Different requirements for signal transducer and activator of transcription 1alpha and interferon regulatory factor 1 in the regulation of low molecular mass polypeptide 2 and transporter associated with antigen processing 1 gene expression. J. Biol. Chem. 273:16177-16183. http://dx.doi.org/10.1074/jbc.273.26.16177
8. Chen, R., T.K. Sigdel, L. Li, N. Kambham, J.T. Dudley, S.-C. Hsieh, R.B. Klassen, A. Chen, T. Caohuu, A.A. Morgan, et al. 2010. Differentially expressed RNA from public microarray data identifies serum protein biomarkers for cross-organ transplant rejection and other conditions. PLOS Comput. Biol. 6.
9. Cheung, A.K., G.A. DeVault Jr., and M.C. Gregory. 1993. A prospective study on treatment of hypercholesterolemia with lovastatin in renal transplant patients receiving cyclosporine. J. Am. Soc. Nephrol. 3:1884-1891.
10. Corry, R.J., and P.S. Russell. 1973. New possibilities for organ allografting in the mouse. In Immunological Aspects of Transplantation Surgery. R.Y. Calne, editor. Medical and Technical Publishing Co., Lancaster. 279-295.
11. Deola, S., M.C. Panelli, D. Maric, S. Selleri, N.I. Dmitrieva, C.Y. Voss, H. Klein, D. Stroncek, E. Wang, and F.M. Marincola. 2008. Helper B cells promote cytotoxic T cell survival and proliferation independently of antigen presentation through CD27/CD70 interactions. J. Immunol. 180:1362-1372
12. Der, S.D., A. Zhou, B.R. Williams, and R.H. Silverman. 1998. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc. Natl. Acad. Sci. USA. 95:15623-15628. http://dx.doi.org/10.1073/pnas.95.26.15623
13. Draghici, S., P. Khatri, A.L. Tarca, K. Amin, A. Done, C. Voichita, C. Georgescu, and R. Romero. 2007. A systems biology approach for pathway level analysis. Genome Res. 17:1537-1545. http://dx.doi.org/10.1101/gr.6202607
14. Drayton, D.L., S. Liao, R.H. Mounzer, and N.H. Ruddle. 2006. Lymphoid organ development: from ontogeny to neogenesis. Nat. Immunol. 7: 344-353. http://dx.doi.org/10.1038/ni1330
15. Dudley, J.T., E. Schadt, M. Sirota, A.J. Butte, and E. Ashley. 2010. Drug discovery in a multidimensional world: systems, patterns, and networks. J. Cardiovasc. Transl. Res. 3:438-447. http://dx.doi.org/10.1007/s12265-010-9214-6
16. Einecke, G., J. Reeve, B. Sis, M. Mengel, L. Hidalgo, K.S. Famulski, A. Matas, B. Kasiske, B. Kaplan, and P.F. Halloran. 2010. A molecular classifier for predicting future graft loss in late kidney transplant biopsies. J. Clin. Invest. 120:1862-1872. http://dx.doi.org/10.1172/JCI41789
17. Ellis, S.L., V. Gysbers, P.M. Manders, W. Li, M.J. Hofer, M. Müller, and I.L. Campbell. 2010. The cell-specific induction of CXC chemokine ligand 9 mediated by IFN-gamma in microglia of the central nervous system is determined by the myeloid transcription factor PU.1. J. Immunol. 185:1864-1877. http://dx.doi.org/10.4049/jimmunol.1000900
18. Ferreira, G.A., A.L. Teixeira, and E.I. Sato. 2010. Atorvastatin therapy reduces interferon-regulated chemokine CXCL9 plasma levels in patients with systemic lupus erythematosus. Lupus. 19:927-934. http://dx.doi.org/10.1177/0961203310364400
19. Fischbein, M.P., A. Ardehali, J. Yun, S. Schoenberger, H. Laks, Y. Irie, P. Dempsey, G. Cheng, M.C. Fishbein, and B. Bonavida. 2000. CD40 signaling replaces CD4+ lymphocytes and its blocking prevents chronic rejection of heart transplants. J. Immunol. 165:7316-7322.
20. Fisher, R.A. 1932. Statistical Methods for Research Workers. Fourth edition. Oliver and Boyd, Edinburgh. 307 pp.
21. Fisher, R.A. 1934. Statistical Methods for Research Workers. Fifth edition. Oliver and Boyd, Edinburgh. 319 pp.
22. Flandre, P., and J. O'Quigley. 2007. Predictive strength of Jonckheere's test for trend: an application to genotypic scores in HIV infection. Stat. Med. 26:4441-4454. http://dx.doi.org/10.1002/sim.2871
23. Goldberg, R., and D. Roth. 1996. Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine. Transplantation. 62:1559-1564. http://dx.doi.org/10.1097/00007890-199612150-00005
24. Grip, O., and S. Janciauskiene. 2009. Atorvastatin reduces plasma levels of chemokine (CXCL10) in patients with Crohn's disease. PLoS ONE. 4:e5263. http://dx.doi.org/10.1371/journal.pone.0005263
25. Guillén, D., F. Cofàn, E. Ros, O. Millàn, M. Cofàn, and M. Brunet. 2010. Biomarker assessment of the immunomodulator effect of atorvastatin in stable renal transplant recipients and hypercholesterolemic patients. Mol. Diagn. Ther. 14:357-366. http://dx.doi.org/10.1007/BF03256393
26. Halloran, P.F. 2004. Immunosuppressive drugs for kidney transplantation. N. Engl. J. Med. 351:2715-2729. http://dx.doi.org/10.1056/NEJMra033540
27. Hartl, M., A. Nist, M.I. Khan, T. Valovka, and K. Bister. 2009. Inhibition of Myc-induced cell transformation by brain acid-soluble protein 1 (BASP1). Proc. Natl. Acad. Sci. USA. 106:5604-5609. http://dx.doi.org/10.1073/pnas.0812101106
28. Holdaas, H., A.G. Jardine, D.C. Wheeler, I.B. Brekke, P.J. Conlon, B. Fellstrøm, A. Hammad, I. Holme, H. Isoniemi, R. Moore, et al. 2001. Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial. Kidney Int. 60:1990-1997. http://dx.doi.org/10.1046/j.1523-1755.2001.00010.x
29. Irizarry, R.A., B.M. Bolstad, F. Collin, L.M. Cope, B. Hobbs, and T.P. Speed. 2003a. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 31:e15. http://dx.doi.org/10.1093/nar/gng015
30. Irizarry, R.A., B. Hobbs, F. Collin, Y.D. Beazer-Barclay, K.J. Antonellis, U. Scherf, and T.P. Speed. 2003b. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 4:249-264. http://dx.doi.org/10.1093/biostatistics/4.2.249
31. Karason, K., M. Jernås, D.A. Hägg, and P.-A. Svensson. 2006. Evaluation of CXCL9 and CXCL10 as circulating biomarkers of human cardiac allograft rejection. BMC Cardiovasc. Disord. 6:29. http://dx.doi.org/10.1186/1471-2261-6-29
32. Kasiske, B.L., K.L. Heim-Duthoy, G.G. Singer, B. Watschinger, M.J. Germain, and B. Bastani. 2001. The effects of lipid-lowering agents on acute renal allograft rejection. Transplantation. 72:223-227. http://dx.doi.org/10.1097/00007890-200107270-00009
33. Katznelson, S., A.H. Wilkinson, J.A. Kobashigawa, X.M. Wang, D. Chia, M. Ozawa, H.P. Zhong, M. Hirata, A.H. Cohen, P.I. Teraski, et al. 1996. The effect of pravastatin on acute rejection after kidney transplantation-a pilot study. Transplantation. 61:1469-1474. http://dx.doi.org/10.1097/00007890-199605270-00010
34. Khatri, P., S. Draghici, A.L. Tarca, S.S. Hassan, and R. Romero. 2007. A system biology approach for the steady-state analysis of gene signaling networks. In Progress in Pattern Recognition, Image Analysis and Applications. L. Rueda, D. Mery, and J. Kittler, editors. Springer-Verlag, Berlin/Heidelberg. 32-41.
35. Kim, Y.C., K.K. Kim, and E.M. Shevach. 2010. Simvastatin induces Foxp3+ T regulatory cells by modulation of transforming growth factorbeta signal transduction. Immunology. 130:484-493. http://dx.doi.org/10.1111/j.1365-2567.2010.03269.x
36. Knight, S.R., N.K. Russell, L. Barcena, and P.J. Morris. 2009. Mycophenolate mofetil decreases acute rejection and may improve graft survival in renal transplant recipients when compared with azathioprine: a systematic review. Transplantation. 87:785-794. http://dx.doi.org/10.1097/TP.0b013e3181952623
37. Kobashigawa, J.A., S. Katznelson, H. Laks, J.A. Johnson, L. Yeatman, X.M. Wang, D. Chia, P.I. Terasaki, A. Sabad, G.A. Cogert, et al. 1995. Effect of pravastatin on outcomes after cardiac transplantation. N. Engl. J. Med. 333:621-627. http://dx.doi.org/10.1056/NEJM199509073331003
38. Kondo, T., K. Morita, Y. Watarai, M.B. Auerbach, D.D. Taub, A.C. Novick, H. Toma, and R.L. Fairchild. 2000. Early increased chemokine expression and production in murine allogeneic skin grafts is mediated by natural killer cells. Transplantation. 69:969-977. http://dx.doi.org/10.1097/00007890-200003150-00051
39. Kuo, P.C., J.M. Kirshenbaum, J. Gordon, G. Laffel, P. Young, V.J. DiSesa, G.H. Mudge Jr., and D.E. Vaughan. 1989. Lovastatin therapy for hypercholesterolemia in cardiac transplant recipients. Am. J. Cardiol. 64: 631-635. http://dx.doi.org/10.1016/0002-9149(89)90492-X
40. Kuznetsov, V.A. 2009. Relative avidity, specificity, and sensitivity of transcription factor-DNA binding in genome-scale experiments. Methods Mol. Biol. 563:15-50. http://dx.doi.org/10.1007/978-1-60761-175-2_2
41. Kwak, B., F. Mulhaupt, S. Myit, and F. Mach. 2000. Statins as a newly recognized type of immunomodulator. Nat. Med. 6:1399-1402. http://dx.doi.org/10.1038/82219
42. Lechler, R.I., M. Sykes, A.W. Thomson, and L.A. Turka. 2005. Organ transplantation-how much of the promise has been realized? Nat. Med. 11:605-613. http://dx.doi.org/10.1038/nm1251
43. Lee, K.C., I. Ouwehand, A.L. Giannini, N.S. Thomas, N.J. Dibb, and M.J. Bijlmakers. 2010. Lck is a key target of imatinib and dasatinib in T-cell activation. Leukemia. 24:896-900. http://dx.doi.org/10.1038/leu.2010.11
44. Li, L., P. Khatri, T.K. Sigdel, T. Tran, L. Ying, M.J. Vitalone, A. Chen, S. Hsieh, H. Dai, M. Zhang, et al. 2012. A peripheral blood diagnostic test for acute rejection in renal transplantation. Am. J. Transplant. 12:2710-2718. http://dx.doi.org/10.1111/j.1600-6143.2012.04253.x
45. Mehra, M.R., P.A. Uber, K. Vivekananthan, S. Solis, R.L. Scott, M.H. Park, R.V. Milani, and C.J. Lavie. 2002. Comparative beneficial effects of simvastatin and pravastatin on cardiac allograft rejection and survival. J. Am. Coll. Cardiol. 40:1609-1614. http://dx.doi.org/10.1016/S0735-1097(02)02340-9
46. Morgun, A., N. Shulzhenko, A. Perez-Diez, R.V.Z. Diniz, G.F. Sanson, D.R. Almeida, P. Matzinger, and M. Gerbase-DeLima. 2006. Molecular profiling improves diagnoses of rejection and infection in transplanted organs. Circ. Res. 98:e74-e83. http://dx.doi.org/10.1161/01.RES.0000228714.15691.8a
47. Mück, W., I. Mai, L. Fritsche, K. Ochmann, G. Rohde, S. Unger, A. Johne, S. Bauer, K. Budde, I. Roots, et al. 1999. Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients. Clin. Pharmacol. Ther. 65:251-261. http://dx.doi.org/10.1016/S0009-9236(99)70104-9
48. Naesens, M., L. Li, L. Ying, P. Sansanwal, T.K. Sigdel, S.-C. Hsieh, N. Kambham, E. Lerut, O. Salvatierra, A.J. Butte, and M.M. Sarwal. 2009. Expression of complement components differs between kidney allografts from living and deceased donors. J. Am. Soc. Nephrol. 20:1839-1851. http://dx.doi.org/10.1681/ASN.2008111145
49. Naesens, M., P. Khatri, L. Li, T.K. Sigdel, M.J. Vitalone, R. Chen, A.J. Butte, O. Salvatierra, and M.M. Sarwal. 2011. Progressive histological damage in renal allografts is associated with expression of innate and adaptive immunity genes. Kidney Int. 80:1364-1376. http://dx.doi.org/10.1038/ki.2011.245
50. Navaneethan, S.D., V. Perkovic, D.W. Johnson, S.U. Nigwekar, J.C. Craig, and G.F. Strippoli. 2009. HMG CoA reductase inhibitors (statins) for kidney transplant recipients. Cochrane Database Syst. Rev. 15:CD005019.
51. Neurauter, G., B. Wirleitner, A. Laich, H. Schennach, G. Weiss, and D. Fuchs. 2003. Atorvastatin suppresses interferon-γ-induced neopterin formation and tryptophan degradation in human peripheral blood mononuclear cells and in monocytic cell lines. Clin. Exp. Immunol. 131:264-267. http://dx.doi.org/10.1046/j.1365-2249.2003.02021.x
52. Nielsen, S.F., B.G. Nordestgaard, and S.E. Bojesen. 2012. Statin use and reduced cancer-related mortality. N. Engl. J. Med. 367:1792-1802. http://dx.doi.org/10.1056/NEJMoa1201735
53. Obara, H., K. Nagasaki, C.L. Hsieh, Y. Ogura, C.O. Esquivel, O.M. Martinez, and S.M. Krams. 2005. IFN-gamma, produced by NK cells that infiltrate liver allografts early after transplantation, links the innate and adaptive immune responses. Am. J. Transplant. 5:2094-2103. http://dx.doi.org/10.1111/j.1600-6143.2005.00995.x
54. Ojo, A.O., H.U. Meier-Kriesche, J.A. Hanson, A.B. Leichtman, D. Cibrik, J.C. Magee, R.A. Wolfe, L.Y. Agodoa, and B. Kaplan. 2000. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation. 69:2405-2409. http://dx.doi.org/10.1097/00007890-200006150-00033
55. Olbricht, C., C. Wanner, T. Eisenhauer, V. Kliem, R. Doll, M. Boddaert, P. O'Grady, M. Krekler, B. Mangold, and U. Christians. 1997.Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. Clin. Pharmacol. Ther. 62:311-321. http://dx.doi.org/10.1016/S0009-9236(97)90034-5
56. Ramasamy, A., A. Mondry, C.C. Holmes, and D.G. Altman. 2008. Key issues in conducting a meta-analysis of gene expression microarray datasets. PLoS Med. 5:e184. http://dx.doi.org/10.1371/journal.pmed.0050184
57. Reeve, J., J. Sellarés, M. Mengel, B. Sis, A. Skene, L. Hidalgo, D.G. de Freitas, K.S. Famulski, and P.F. Halloran. 2013. Molecular diagnosis of T cell-mediated rejection in human kidney transplant biopsies. Am. J. Transplant. 13:645-655. http://dx.doi.org/10.1111/ajt.12079
58. Regazzi, M.B., I. Iacona, C. Campana, V. Raddato, C. Lesi, G. Perani, A. Gavazzi, and M. Viganò. 1993. Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. Transplant. Proc. 25:2732-2734.
59. Renders, L., I. Mayer-Kadner, C. Koch, S. Schärffe, K. Burkhardt, R. Veelken, R.E. Schmieder, and I.A. Hauser. 2001. Efficacy and drug interactions of the new HMG-CoA reductase inhibitors cerivastatin and atorvastatin in CsA-treated renal transplant recipients. Nephrol. Dial. Transplant. 16:141-146. http://dx.doi.org/10.1093/ndt/16.1.141
60. Robertson, G., M. Hirst, M. Bainbridge, M. Bilenky, Y. Zhao, T. Zeng, G. Euskirchen, B. Bernier, R. Varhol, A. Delaney, et al. 2007. Genomewide profiles of STAT1 DNA association using chromatin immunoprecipitation and massively parallel sequencing. Nat. Methods. 4:651-657. http://dx.doi.org/10.1038/nmeth1068
61. Sakaeda, Y., M. Hiroi, T. Shimojima, M. Iguchi, H. Kanegae, and Y. Ohmori. 2006. Sulindac, a nonsteroidal anti-inflammatory drug, selectively inhibits interferon-γ-induced expression of the chemokine CXCL9 gene in mouse macrophages. Biochem. Biophys. Res. Commun. 350:339-344. http://dx.doi.org/10.1016/j.bbrc.2006.09.058
62. Sarwal, M., M.-S. Chua, N. Kambham, S.-C. Hsieh, T. Satterwhite, M. Masek, and O.J. Salvatierra Jr. 2003. Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N. Engl. J. Med. 349:125-138. http://dx.doi.org/10.1056/NEJMoa035588
63. Schade, A.E., G.L. Schieven, R. Townsend, A.M. Jankowska, V. Susulic, R. Zhang, H. Szpurka, and J.P. Maciejewski. 2008. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood. 111:1366-1377. http://dx.doi.org/10.1182/blood-2007-04-084814
64. Shah, N.P., H.M. Kantarjian, D.W. Kim, D. Réa, P.E. Dorlhiac-Llacer, J.H. Milone, J. Vela-Ojeda, R.T. Silver, H.J. Khoury, A. Charbonnier, et al. 2008. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J. Clin. Oncol. 26:3204-3212. http://dx.doi.org/10.1200/JCO.2007.14.9260
65. Sharif, M.N., I. Tassiulas, Y. Hu, I. Mecklenbräuker, A. Tarakhovsky, and L.B. Ivashkiv. 2004. IFN-alpha priming results in a gain of proinflammatory function by IL-10: implications for systemic lupus erythematosus pathogenesis. J. Immunol. 172:6476-6481.
66. Shi, S., A. Blumenthal, C.M. Hickey, S. Gandotra, D. Levy, and S. Ehrt. 2005. Expression of many immunologically important genes in Mycobacterium tuberculosis-infected macrophages is independent of both TLR2 and TLR4 but dependent on IFN-alphabeta receptor and STAT1. J. Immunol. 175:3318-3328.
67. Snyder, T.M., K.K. Khush, H.A. Valantine, and S.R. Quake. 2011. Universal noninvasive detection of solid organ transplant rejection. Proc. Natl. Acad. Sci. USA. 108:6229-6234. http://dx.doi.org/10.1073/pnas.1013924108 Storey, J.D. 2002. A direct approach to false discovery rates. J. R. Stat. Soc., B. 64:479-498. http://dx.doi.org/10.1111/1467-9868.00346
68. Storey, J.D. 2002. A direct approach to false discovery rates. J. R. Stat. Soc., B. 64:479-498. http://dx.doi.org/10.1111/1467-9868.00346
69. Su, A.I., T. Wiltshire, S. Batalov, H. Lapp, K.A. Ching, D. Block, J. Zhang, R. Soden, M. Hayakawa, G. Kreiman, et al. 2004. A gene atlas of the mouse and human protein-encoding transcriptomes. Proc. Natl. Acad. Sci. USA. 101:6062-6067. http://dx.doi.org/10.1073/pnas.0400782101
70. Tarca, A.L., S. Draghici, P. Khatri, S.S. Hassan, P. Mittal, J.-S. Kim, C.J. Kim, J.P. Kusanovic, and R. Romero. 2009. A novel signaling pathway impact analysis. Bioinformatics. 25:75-82. http://dx.doi.org/10.1093/bioinformatics/btn577
71. Vajdic, C.M., S.P. McDonald, M.R. McCredie, M.T. van Leeuwen, J.H. Stewart, M. Law, J.R. Chapman, A.C. Webster, J.M. Kaldor, and A.E. Grulich. 2006. Cancer incidence before and after kidney transplantation. JAMA. 296:2823-2831. http://dx.doi.org/10.1001/jama.296.23.2823
72. van Leuven, S.I., D.F. van Wijk, O.L. Volger, J.-P.P.M. de Vries, C.M. van der Loos, D.V.P. de Kleijn, A.J.G. Horrevoets, P.P. Tak, A.C. van der Wal, O.J. de Boer, et al. 2010. Mycophenolate mofetil attenuates plaque inflammation in patients with symptomatic carotid artery stenosis. Atherosclerosis. 211:231-236. http://dx.doi.org/10.1016/j.atherosclerosis.2010.01.043
73. Walsh, R.C., J.J. Everly, P. Brailey, A.H. Rike, L.J. Arend, G. Mogilishetty, A. Govil, P. Roy-Chaudhury, R.R. Alloway, and E.S. Woodle. 2010. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection. Transplantation. 89:277-284. http://dx.doi.org/10.1097/TP.0b013e3181c6ff8d
74. Wang, E., A. Worschech, and F.M. Marincola. 2008. The immunologic constant of rejection. Trends Immunol. 29:256-262. http://dx.doi.org/10.1016/j.it.2008.03.002
75. Xu, F., Z.H. Wu, Z.Y. Zhang, and H.Q. Zou. 1998. Delay of metabolism rate of ciclosporin by simvastatin in 7 Chinese healthy men. Zhongguo Yao Li Xue Bao. 19:443-444.
76. Yilmaz, S., S. Tomlanovich, T. Mathew, E. Taskinen, T. Paavonen, M. Navarro, E. Ramos, L. Hooftman, and P. Häyry. 2003. Protocol core needle biopsy and histologic Chronic Allograft Damage Index (CADI) as surrogate end point for long-term graft survival in multicenter studies. J. Am. Soc. Nephrol. 14:773-779. http://dx.doi.org/10.1097/01.ASN.0000054496.68498.13
77. Zhao, D.X.-M., Y. Hu, G.G. Miller, A.D. Luster, R.N. Mitchell, and P. Libby. 2002. Differential expression of the IFN-gamma-inducible CXCR3-binding chemokines, IFN-inducible protein 10, monokine induced by IFN, and IFN-inducible T cell alpha chemoattractant in human cardiac allografts: association with cardiac allograft vasculopathy and acute rejection. J. Immunol. 169:1556-1560.